Rectal Cancer Clinical Trial
— EXERTOfficial title:
A Phase II Randomized Controlled Trial of Aerobic Exercise in Rectal Cancer Patients During and After Neoadjuvant Chemoradiotherapy
Verified date | March 2022 |
Source | University of Alberta |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is designed to investigate if aerobic exercise during and after neoadjuvant chemoradiotherapy (NACRT) can improve outcomes for rectal cancer patients.
Status | Completed |
Enrollment | 36 |
Est. completion date | September 1, 2020 |
Est. primary completion date | October 17, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - All patients scheduled to receive long-course (5-6 weeks) of NACRT followed by total mesorectal excision Exclusion Criteria: - Unable to consent - Unable to perform aerobic exercise - Intention to engage in a structured exercise program during NACRT and/or after NACRT and prior to surgery |
Country | Name | City | State |
---|---|---|---|
Canada | Cross Cancer Institute | Edmonton | Alberta |
Lead Sponsor | Collaborator |
---|---|
University of Alberta | Canadian Cancer Society (CCS) |
Canada,
Morielli AR, Boulé NG, Usmani N, Tankel K, Joseph K, Severin D, Fairchild A, Nijjar T, Courneya KS. Effects of exercise during and after neoadjuvant chemoradiation on symptom burden and quality of life in rectal cancer patients: a phase II randomized controlled trial. J Cancer Surviv. 2021 Nov 29. doi: 10.1007/s11764-021-01149-w. [Epub ahead of print] — View Citation
Morielli AR, Usmani N, Boulé NG, Severin D, Tankel K, Joseph K, Nijjar T, Fairchild A, Courneya KS. Feasibility, Safety, and Preliminary Efficacy of Exercise During and After Neoadjuvant Rectal Cancer Treatment: A Phase II Randomized Controlled Trial. Clin Colorectal Cancer. 2021 Sep;20(3):216-226. doi: 10.1016/j.clcc.2021.05.004. Epub 2021 May 26. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Treatment toxicities | CTCAE Version 3.0 | every week during NACRT (up to 6 weeks) | |
Other | Number of patients completing 100% of their planned radiation dose within 1 week of planned completion date | Obtained from electronic medical records | post-NACRT (an average of 6 weeks) | |
Other | Number of patients receiving = 80% of their planned chemotherapy dose | Obtained from electronic medical records | post-NACRT (an average of 6 weeks) | |
Other | Pathologic complete response rate | Obtained from electronic medical records | post-surgery (an average of 12 weeks) | |
Other | Length of hospital stay | Obtained from electronic medical records | post-surgery (an average of 12 weeks) | |
Other | Surgical approach | Obtained from electronic medical records | post-surgery (an average of 12 weeks) | |
Other | Ostomy | Obtained from electronic medical records | post-surgery (an average of 12 weeks) | |
Other | Sphincter preservation | Obtained from electronic medical records | post-surgery (an average of 12 weeks) | |
Other | Blood loss | Obtained from electronic medical records | post-surgery (an average of 12 weeks) | |
Other | Number of positive lymph nodes | Obtained from electronic medical records | post-surgery (an average of 12 weeks) | |
Primary | Change in Cardiorespiratory fitness | VO2 peak | pre-NACRT (baseline), post-NACRT (an average of 6 weeks) | |
Secondary | Cardiorespiratory fitness | VO2 peak | pre-surgery (an average of 12 weeks) | |
Secondary | Functional fitness | Senior's Fitness Test | pre-NACRT (baseline), post-NACRT (an average of 6 weeks), pre-surgery (an average of 12 weeks) | |
Secondary | Generic quality of life | European Organisation for Research and Treatment of Cancer core 30-item questionnaire | pre-NACRT (baseline), post-NACRT (an average of 6 weeks), pre-surgery (an average of 12 weeks) | |
Secondary | Disease specific quality of life | European Organisation for Research and Treatment of Cancer questionnaire module for colorectal cancer | pre-NACRT (baseline), post-NACRT (an average of 6 weeks), pre-surgery (an average of 12 weeks) | |
Secondary | Symptom burden | M.D. Anderson Symptom Inventory | pre-NACRT (baseline), post-NACRT (an average of 6 weeks), pre-surgery (an average of 12 weeks) | |
Secondary | Exercise motivation | Theory of planned behaviour | pre-NACRT (baseline), post-NACRT (an average of 6 weeks), pre-surgery (an average of 12 weeks) | |
Secondary | Eligibility rate | Number of eligible patients divided by the number of rectal cancer patients scheduled to receive long-course NACRT | up to 20 months | |
Secondary | Recruitment rate | Number of patients randomized divided by the number of eligible patients | up to 20 months | |
Secondary | Exercise adherence rate | Exercise adherence during NACRT will be assessed by the number of exercise sessions attended out of 18 as well as adherence to the intensity and duration of the HIT intervals. Exercise adherence to the unsupervised exercise after NACRT will be assessed by self-report using the Godin Leisure-Time Exercise. | post-NACRT (an average of 6 weeks), pre-surgery (an average of 12 weeks) | |
Secondary | Follow-up assessment rate | Number of patients in each group completing the objective outcomes (cardiorespiratory fitness and functional fitness) and patient-reported outcomes (quality of life, symptom burden) at each timepoint. | post-NACRT (an average of 6 weeks), pre-surgery (an average of 12 weeks) | |
Secondary | Safety: Adverse event rate | Number of serious adverse events that occur during exercise testing or the supervised exercise sessions | post-NACRT (an average of 6 weeks), pre-surgery (an average of 12 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06380101 -
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
|
N/A | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Recruiting |
NCT04323722 -
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Active, not recruiting |
NCT01347697 -
Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer
|
N/A | |
Recruiting |
NCT04495088 -
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
|
Phase 3 | |
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03520088 -
PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS
|
N/A | |
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Recruiting |
NCT04749381 -
The Role of TCM on ERAS of Rectal Cancer Patients
|
Phase 2 | |
Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
Recruiting |
NCT03283540 -
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Recruiting |
NCT05914766 -
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
|
N/A | |
Recruiting |
NCT04852653 -
A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
|
||
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Terminated |
NCT02933944 -
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A |